Cigna National Formulary Coverage Policy

Prior Authorization
Metabolic Disorders – Dojolvi™ (triheptanoin oral liquid)

Table of Contents

National Formulary Medical Necessity ................ 1
Conditions Not Covered....................................... 2
Background.......................................................... 2
References .......................................................... 3
Revision History ...................................................... 3

INSTRUCTIONS FOR USE
The following Coverage Policy applies to health benefit plans administered by Cigna Companies. Certain Cigna Companies and/or lines of business only provide utilization review services to clients and do not make coverage determinations. References to standard benefit plan language and coverage determinations do not apply to those clients. Coverage Policies are intended to provide guidance in interpreting certain standard benefit plans administered by Cigna Companies. Please note, the terms of a customer’s particular benefit plan document [Group Service Agreement, Evidence of Coverage, Certificate of Coverage, Summary Plan Description (SPD) or similar plan document] may differ significantly from the standard benefit plans upon which these Coverage Policies are based. For example, a customer’s benefit plan document may contain a specific exclusion related to a topic addressed in a Coverage Policy. In the event of a conflict, a customer’s benefit plan document always supersedes the information in the Coverage Policies. In the absence of a controlling federal or state coverage mandate, benefits are ultimately determined by the terms of the applicable benefit plan document. Coverage determinations in each specific instance require consideration of 1) the terms of the applicable benefit plan document in effect on the date of service; 2) any applicable laws/regulations; 3) any relevant collateral source materials including Coverage Policies and; 4) the specific facts of the particular situation. Coverage Policies relate exclusively to the administration of health benefit plans. Coverage Policies are not recommendations for treatment and should never be used as treatment guidelines. In certain markets, delegated vendor guidelines may be used to support medical necessity and other coverage determinations.

National Formulary Medical Necessity

Cigna covers triheptanoin (Dojolvi™) as medically necessary when the following criteria are met for FDA Indications or Other Uses with Supportive Evidence:

Prior Authorization is recommended for prescription benefit coverage of Dojolvi. All approvals are provided for the duration noted below. Because of the specialized skills required for evaluation and diagnosis of individuals treated with Dojolvi as well as the monitoring required for adverse events and long-term efficacy, approval requires Dojolvi to be prescribed by or in consultation with a physician who specializes in the condition being treated.

FDA Indication(s)

1. Long-Chain Fatty Acid Oxidation Disorders. Approve for 1 year if the individual meets the following criteria (A, B, C, and D):
   A) Individual has a molecularly confirmed diagnosis of a long-chain fatty acid oxidation disorder based on at least TWO of the following (TWO of i, ii, or iii):
      i. Disease-specific elevations of acylcarnitines on a newborn blood spot or in plasma; OR
ii. Enzyme activity assay (in cultured fibroblasts or lymphocytes) below the lower limit of the normal reference range for the reporting laboratory; OR
   Note: Examples of enzyme assays include carnitine palmitoyl transferase 2 (CPT-2), very long-chain acyl-CoA dehydrogenase (VLCAD), long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD), and mitochondrial trifunctional protein (TFP).

iii. Genetic testing demonstrating pathogenic mutation in a gene associated with long-chain fatty acid oxidation disorders; AND
   Note: Examples of genes associated with long-chain fatty acid disorders include CPT2 (encodes CPT-2), ACADVL (encodes VLCAD), HADHA (encodes LCHAD and TFP), and HADHB (encodes TFP).

B) Individual will not use any other medium-chain triglyceride products concomitantly with Dojolvi; AND
C) Individual meets at least one of the following (i, ii, or iii):
   i. According to the prescriber, the individual has had inadequate efficacy or significant intolerance to an over-the-counter (nutraceutical supplements) medium-chain triglyceride product (other than Dojolvi); OR
   ii. According to the prescriber, the individual has a history of at least one severe or recurrent manifestation of long-chain fatty acid oxidation disorders (i.e., cardiomyopathy, rhabdomyolysis, or hypoglycemia); OR
   iii. Individual is currently receiving Dojolvi; AND
D) The medication is prescribed by, or in consultation with, a metabolic disease specialist or a physician who specializes in the management of long-chain fatty acid oxidation disorders.

Conditions Not Covered

Triheptanoin (Dojolvi™) is considered experimental, investigational or unproven for ANY other use.

Background

Overview
Dojolvi, a synthetic medium odd-chain triglyceride, is indicated as a source of calories and fatty acids for the treatment of adults and pediatric patients with molecularly confirmed long-chain fatty acid oxidation disorders (LC-FAODs).1

For a patient receiving another medium-chain triglyceride product, discontinue prior to the first dose of Dojolvi.

Disease Overview
LC-FAODs are a group of autosomal recessive genetic metabolic disorders in which the body is unable to properly oxidize long-chain fatty acid in the mitochondria (normally an important energy pathway when glucose is low).2,3 The four most commonly affected enzymes are carnitine palmitoyl transferase 2 (CPT-2), very long-chain acyl-CoA dehydrogenase (VLCAD), long-chain 3-hydroxyacyl-CoA dehydrogenase (LCHAD), and mitochondrial trifunctional protein (TFP).4 Other less common mutations may also occur.5,4 Onset may occur anywhere from the neonatal period to adulthood. Clinical manifestations are heterogeneous and not well correlated with genotype.2 Diagnosis of LC-FAODs has increased with the use of routine newborn screening. Newborn screening tests measure acylcarnitines in dried blood spots.5 Abnormal newborn screening results or the presence of symptoms associated with LC-FAODs warrant further evaluation involving plasma acylcarnitine measurement, enzyme activity assays, and/or genetic testing. The activity of specific enzymes can be measured in lymphocytes or skin fibroblasts since these cells express all enzymes involved in long-chain fatty acid oxidation.3 Mutation analysis can identify the specific genetic defect. However, new mutations and variants are regularly identified, requiring functional studies such as enzyme activity measurements for confirmation of the diagnosis.

Guidelines
A consensus statement regarding treatment recommendations in LC-FAODs was published in 2009; Dojolvi is not specifically addressed, although medium-chain triglycerides (MCT) are discussed more broadly.6 In general,
it is noted that the clinical course of LC-FAODs is unpredictable, and MCT supplementation is an important part of the management strategy for many patients.

References


Revision History

<table>
<thead>
<tr>
<th>Type of Revision</th>
<th>Summary of Changes</th>
<th>Review Date</th>
</tr>
</thead>
<tbody>
<tr>
<td>Annual Revision</td>
<td>No criteria changes.</td>
<td>07/14/2021</td>
</tr>
</tbody>
</table>

“Cigna Companies” refers to operating subsidiaries of Cigna Corporation. All products and services are provided exclusively by or through such operating subsidiaries, including Cigna Health and Life Insurance Company, Connecticut General Life Insurance Company, Cigna Behavioral Health, Inc., Cigna Health Management, Inc., QualCare, Inc., and HMO or service company subsidiaries of Cigna Health Corporation. The Cigna name, logo, and other Cigna marks are owned by Cigna Intellectual Property, Inc. © 2021 Cigna.